Table 1. Baseline characteristics of hospitalized severe or critical COVID-19 patients by vaccine status.
| Total n = 349 | No vaccine n = 202 | Two Vaccines n = 122 | Booster n = 25 | P | |
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | ||
| Age, mean ± SD, y | 67.7± 17.1 | 64± 17 | 72± 16 | 78 ±10 | <0.001 |
| Age ≤ 50 y | 64 (18) | 52 (26) | 12 (10) | 0 | |
| Age > 50 y | 285 (82) | 150 (74) | 110 (90) | 25 (100) | <0.001 |
| Male gender | 200 (57) | 103 (51) | 82 (67) | 15(60) | 0.016 |
| HTN | 186 (53) | 99 (49) | 70 (57) | 17 (68) | 0.107 |
| Hyperlipidemia | 145 (41.5) | 73 (36) | 57 (47) | 15 (60) | 0.026 |
| DM | 112 (32) | 55 (27) | 44 (36) | 13 (52) | 0.022 |
| Obesity (BMI≥30) | 106 (30) | 59 (29) | 43 (35) | 4 (16) | 0.139 |
| COPD | 51 (15) | 30 (15) | 18 (15) | 3 (12) | 0.929 |
| IHD | 68 (19.5) | 24 (12) | 35 (29) | 9 (36) | <0.001 |
| HF | 57 (16) | 25 (12) | 23 (19) | 9 (36) | 0.007 |
| AF | 47 (13.5) | 23 (11) | 17 (14) | 7 (28) | 0.070 |
| Immuno-deficiency ª | 40 (11.5) | 14 (7) | 19 (16) | 7 (28) | 0.002 |
| cirrhosis | 3 (0.9) | 2 | 1 | 0 | 0.878 |
| CKD | 44 (12.6) | 14 (7) | 26 (21) | 4 (16) | <0.001 |
| Cognitive decline | 70 (20) | 31 (15) | 30 (25) | 9 (36) | 0.016 |
| number of total comorbidities | 2.5 ±2.0 | 2.1± 1.9 | 3.0 ±2.0 | 3.5± 2.4 | <0.001 |
| Symptoms to hosp. b | 6.45± 4.36 | 7.2± 4.4 | 5.4± 4.1 | 5.6 ±4.6 | 0.002 |
| PCR to hosp. b | 4.56± 4.69 | 4.7± 4.5 | 4.3 ±4.4 | 4.6± 6.8 | 0.792 |
Abbreviations: y, year; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index; COPD, Chronic Obstructive Pulmonary Disease; IHD, ischemic heart disease; HF, heart failure; AF, atrial fibrillation; CKD, chronic kidney disease.
ª Patients included are those with Immunodeficiency secondary to immuno-suppressive therapy or lymphoproliferative malignancy.
b Mean number of days from symptoms or from first positive SARS-COV-2 PCR test to hospital admission.